Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the
immune response. While for decades the field isolated lytic capability and viral spread to …

Malignant melanoma outcomes have drastically changed in recent years due to the
introduction of immune checkpoint inhibitors (ICIs). However, many patients still experience …

Despite good results in the treatment of hematological malignancies, Natural killer (NK) cells
have shown limited effectiveness in solid tumors, such as ovarian cancer (OvCa). Here, we …

T cell-focused cancer immunotherapy including checkpoint inhibitors and cell therapies has
been rapidly evolving over the past decade. Nevertheless, there remains a major unmet …

Ovarian cancer (OC) remains the most lethal gynecologic malignancy with limited effective
treatment options. Oncolytic viruses (OVs) have emerged as a promising therapeutic …

This review article provides a comprehensive overview of a novel Sindbis virus vaccine
platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most …

Advanced ovarian cancer is a difficult-to-treat disease and frequently associated with
malignant ascites, a condition characterized by abnormal peritoneal accumulation of fluid …

Human adenovirus type 5 (HAdV-5)-based oncolytic virotherapy holds promise as efficient
anti-cancer therapy. Beside a direct virus-induced cancer cell lysis, the resultant release of …

Oncolytic viruses are viruses which lyse tumor cells and stimulate a patient specific anti-
tumor and anti-viral immune response. While one oncolytic virus has received FDA …

Bispecific T cell engager (BsTe) therapy can harness the power of T cells and enhances
antitumor activity. In a clinical setting, this therapy has proven efficacy in treating uveal and …